Peter Tan

669 total citations
18 papers, 252 citations indexed

About

Peter Tan is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Peter Tan has authored 18 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 7 papers in Genetics and 6 papers in Immunology. Recurrent topics in Peter Tan's work include Acute Myeloid Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Peter Tan is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Peter Tan collaborates with scholars based in Australia, United States and United Kingdom. Peter Tan's co-authors include Andrew H. Wei, Magdalena Plebanski, Andrew Spencer, Patricia Walker, Ying Kong, Mutsa Madondo, Sushrut Patil, Marian Sturm, Julie F. McManus and Shaun Fleming and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Peter Tan

17 papers receiving 249 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Tan Australia 10 126 109 85 55 33 18 252
Mélanie Pannetier France 3 161 1.3× 157 1.4× 75 0.9× 82 1.5× 50 1.5× 6 284
Lorenz Bastian Germany 7 73 0.6× 86 0.8× 80 0.9× 55 1.0× 29 0.9× 24 209
Stephan Bohl Germany 8 159 1.3× 176 1.6× 89 1.0× 56 1.0× 39 1.2× 16 329
Daniel Egan United States 8 127 1.0× 79 0.7× 49 0.6× 123 2.2× 33 1.0× 22 212
Sung‐Soo Yoon South Korea 9 152 1.2× 120 1.1× 35 0.4× 91 1.7× 58 1.8× 54 272
Amanda R. Leonti United States 8 113 0.9× 99 0.9× 35 0.4× 55 1.0× 36 1.1× 32 193
Hanna A. Knaus Austria 8 183 1.5× 87 0.8× 182 2.1× 149 2.7× 35 1.1× 21 317
Jean‐Valère Malfuson France 8 143 1.1× 142 1.3× 32 0.4× 50 0.9× 42 1.3× 15 250
A Orfao Spain 6 121 1.0× 58 0.5× 97 1.1× 40 0.7× 28 0.8× 7 239
Seo-Yeon Ahn South Korea 7 123 1.0× 51 0.5× 65 0.8× 73 1.3× 47 1.4× 26 215

Countries citing papers authored by Peter Tan

Since Specialization
Citations

This map shows the geographic impact of Peter Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Tan more than expected).

Fields of papers citing papers by Peter Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Tan. The network helps show where Peter Tan may publish in the future.

Co-authorship network of co-authors of Peter Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Tan. A scholar is included among the top collaborators of Peter Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Tan. Peter Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lele, Abhijit V., Hemanshu Prabhakar, Charu Mahajan, et al.. (2025). External Ventricular Drain Management in Aneurysmal Subarachnoid Hemorrhage: Perspectives and Practices From Low-Income and Middle-Income Countries. Cureus. 17(4). e83265–e83265.
2.
Dhakal, Binod, Hang Quach, Andrew Spencer, et al.. (2024). Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3364–3364. 1 indexed citations
3.
Tan, Peter, Ross Baker, Sung‐Eun Lee, et al.. (2024). Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis. Blood. 144(Supplement 1). 1001–1001. 1 indexed citations
4.
Kazandjian, Dickran, Hang Quach, Hanlon Sia, et al.. (2023). Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM). Blood. 142(Supplement 1). 4707–4707. 5 indexed citations
5.
6.
7.
Taussig, David, Jenny O’Nions, Mojca Jongen‐Lavrencic, et al.. (2022). EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood. 140(Supplement 1). 6222–6223. 1 indexed citations
8.
DiNardo, Courtney D., Anthony S. Stein, Eytan M. Stein, et al.. (2019). Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).. Journal of Clinical Oncology. 37(15_suppl). 7011–7011. 21 indexed citations
9.
10.
Tan, Peter, et al.. (2017). Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation. 24(3). 433–442. 14 indexed citations
11.
Rabbolini, David J., Maya Latimer, Shinji Kunishima, et al.. (2017). Diagnosis and treatment ofMYH9-RD in an Australasian cohort with thrombocytopenia. Platelets. 29(8). 793–800. 14 indexed citations
12.
Tan, Peter, Ing Soo Tiong, Shaun Fleming, et al.. (2016). The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget. 8(32). 52269–52280. 20 indexed citations
13.
Wei, Andrew H., Peter Tan, Shaun Fleming, et al.. (2015). Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia. British Journal of Haematology. 169(2). 199–210. 25 indexed citations
14.
Madondo, Mutsa, et al.. (2014). Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology. 89(8). 795–802. 38 indexed citations
15.
16.
Tan, Peter & Andrew H. Wei. (2011). The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. Pathology. 43(6). 536–546. 9 indexed citations
17.
Wei, Andrew H., Peter Tan, John Catalano, et al.. (2011). Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. Blood. 118(21). 2599–2599. 2 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mélanie Pannetier Breakdown of academic impact, for papers by Lorenz Bastian Breakdown of academic impact, for papers by Stephan Bohl Breakdown of academic impact, for papers by Daniel Egan Breakdown of academic impact, for papers by Sung‐Soo Yoon Breakdown of academic impact, for papers by Amanda R. Leonti Breakdown of academic impact, for papers by Hanna A. Knaus Breakdown of academic impact, for papers by Jean‐Valère Malfuson Breakdown of academic impact, for papers by A Orfao Breakdown of academic impact, for papers by Seo-Yeon Ahn
Rankless by CCL
2026